DDEF2 Activators
DDEF2 Activators comprise various compounds that indirectly stimulate the activity of DDEF2, a protein encoded by the ASAP2 gene and involved in the regulation of small GTPases, crucial for numerous cellular functions. Growth factors such as Epidermal Growth Factor (EGF) plays a significant role in enhancing DDEF2 activity. EGF activates EGFR signaling, leading to downstream events that can increase DDEF2's GTPase-activating protein (GAP) activity, thus influencing cell migration and cytoskeletal remodeling. Additionally, PMA, a protein kinase C (PKC) activator, influences DDEF2 by modifying small GTPase activity, affecting cellular processes such as vesicular trafficking.
Metabolic regulators like Insulin and IGF-1 also indirectly augment DDEF2's activity. Insulin receptor signaling modulates small GTPase activity, a key target of DDEF2, thus influencing insulin-mediated processes like glucose uptake. IGF-1, through its receptor signaling, potentially enhances DDEF2's GAP activity, impacting cell growth and survival. Furthermore, agents such as Erlotinib Hydrochloride and Dasatinib can modulate DDEF2 activity under specific conditions by altering signaling pathways and affecting small GTPase activity. Erlotinib Hydrochloride, by inhibiting EGFR, and Dasatinib, by targeting Src family kinases, may lead to compensatory mechanisms that enhance DDEF2's GAP activity. Additionally, Adenosine 3',5'-cyclic monophosphate and Forskolin, by influencing various signaling pathways, can enhance DDEF2's regulatory role in cellular responses such as migration and proliferation. Lastly, TGF-β and Rapamycin, through their respective signaling pathways, can modulate DDEF2 activity, influencing processes like cellular differentiation, growth, and autophagy. These activators, through their diverse mechanisms, underscore the multifaceted role of DDEF2 in regulating cellular dynamics and signaling pathways.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
PMA | 16561-29-8 | sc-3576 sc-3576A sc-3576B sc-3576C sc-3576D | 1 mg 5 mg 10 mg 25 mg 100 mg | $41.00 $132.00 $214.00 $500.00 $948.00 | 119 | |
PMA, a PKC activator, indirectly enhances DDEF2 activity. PKC activation can lead to phosphorylation events that modify the activity of small GTPases, which are regulated by DDEF2. This modulation can increase DDEF2's GAP activity toward these GTPases, affecting cellular processes like vesicular trafficking. | ||||||
Insulin | 11061-68-0 | sc-29062 sc-29062A sc-29062B | 100 mg 1 g 10 g | $156.00 $1248.00 $12508.00 | 82 | |
Insulin indirectly enhances DDEF2 activity. Insulin receptor signaling can modulate small GTPase activity, which DDEF2 regulates. This modulation may increase DDEF2's GAP activity, influencing insulin-mediated processes like glucose uptake and metabolic regulation. | ||||||
Erlotinib Hydrochloride | 183319-69-9 | sc-202154 sc-202154A | 10 mg 25 mg | $75.00 $121.00 | 33 | |
Erlotinib Hydrochloride, while an EGFR inhibitor, may indirectly enhance DDEF2 activity under specific conditions. By inhibiting EGFR, Erlotinib Hydrochloride alters downstream signaling pathways, potentially leading to compensatory mechanisms that enhance DDEF2's GAP activity toward other small GTPases, affecting cell signaling and migration. | ||||||
Adenosine 3′,5′-cyclic monophosphate | 60-92-4 | sc-217584 sc-217584A sc-217584B sc-217584C sc-217584D sc-217584E | 100 mg 250 mg 5 g 10 g 25 g 50 g | $116.00 $179.00 $265.00 $369.00 $629.00 $1150.00 | ||
Adenosine 3',5'-cyclic monophosphate indirectly enhances DDEF2 activity. Elevated Adenosine 3',5'-cyclic monophosphate levels can affect various signaling pathways, potentially influencing small GTPase activity that DDEF2 regulates. This could lead to enhanced DDEF2 GAP activity, impacting cellular responses such as cell migration and proliferation. | ||||||
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $78.00 $153.00 $740.00 $1413.00 $2091.00 | 73 | |
Forskolin, by elevating cAMP levels, indirectly enhances DDEF2 activity. Increased cAMP can modulate signaling pathways affecting small GTPase activity, which DDEF2 regulates. This modulation may increase DDEF2's GAP activity, influencing processes like vesicular trafficking and cytoskeletal dynamics. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $70.00 $145.00 | 51 | |
Dasatinib, a Src family kinase inhibitor, can indirectly enhance DDEF2 activity. By inhibiting Src kinases, it may alter signaling pathways that affect small GTPases regulated by DDEF2. This alteration could lead to increased DDEF2 GAP activity, impacting cellular processes like migration and adhesion. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin, an mTOR inhibitor, indirectly enhances DDEF2 activity. By inhibiting mTOR, Rapamycin can affect downstream signaling pathways, potentially enhancing DDEF2's regulation of small GTPases. This might lead to increased DDEF2 GAP activity, affecting processes like cell growth and autophagy. | ||||||
Guanosine 5′-O-(3-thiotriphosphate) tetralithium salt | 94825-44-2 | sc-202639 | 10 mg | $465.00 | ||
GTPγS, a non-hydrolyzable GTP analog, indirectly enhances DDEF2 activity. GTPγS binds to GTPases, mimicking the GTP-bound state. This binding can facilitate the study of DDEF2's GAP activity towards these GTPases, potentially enhancing our understanding of its role in cellular signaling and dynamics. | ||||||